Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of EUR 648.02 million. The enterprise value is 660.20 million.

Market Cap	648.02M
Enterprise Value	660.20M

Important Dates

The last earnings date was Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharming Group has 683.93 million shares outstanding. The number of shares has increased by 2.22% in one year.

Current Share Class	683.93M
Shares Outstanding	683.93M
Shares Change (YoY)	+2.22%
Shares Change (QoQ)	-9.59%
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	8.67%
Float	669.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.18
PB Ratio	3.25
P/TBV Ratio	9.32
P/FCF Ratio	137.55
P/OCF Ratio	115.12
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.85, with an EV/FCF ratio of 140.14.

EV / Earnings	-50.57
EV / Sales	2.23
EV / EBITDA	37.85
EV / EBIT	59.47
EV / FCF	140.14

Financial Position

The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.55.

Current Ratio	2.76
Quick Ratio	2.00
Debt / Equity	0.55
Debt / EBITDA	5.86
Debt / FCF	23.40
Interest Coverage	1.10

Financial Efficiency

Return on equity (ROE) is -6.78% and return on invested capital (ROIC) is 2.38%.

Return on Equity (ROE)	-6.78%
Return on Assets (ROA)	1.99%
Return on Invested Capital (ROIC)	2.38%
Return on Capital Employed (ROCE)	4.14%
Revenue Per Employee	734,453
Profits Per Employee	-32,318
Employee Count	404
Asset Turnover	0.76
Inventory Turnover	0.61

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.04% in the last 52 weeks. The beta is 0.44, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.44
52-Week Price Change	+12.04%
50-Day Moving Average	0.78
200-Day Moving Average	0.79
Relative Strength Index (RSI)	70.67
Average Volume (20 Days)	11,908,608

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of EUR 296.72 million and -13.06 million in losses. Loss per share was -0.02.

Revenue	296.72M
Gross Profit	264.03M
Operating Income	12.47M
Pretax Income	-3.38M
Net Income	-13.06M
EBITDA	15.68M
EBIT	12.47M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 99.25 million in cash and 110.23 million in debt, giving a net cash position of -10.98 million or -0.02 per share.

Cash & Cash Equivalents	99.25M
Total Debt	110.23M
Net Cash	-10.98M
Net Cash Per Share	-0.02
Equity (Book Value)	199.19M
Book Value Per Share	0.30
Working Capital	126.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.63 million and capital expenditures -917,798, giving a free cash flow of 4.71 million.

Operating Cash Flow	5.63M
Capital Expenditures	-917,798
Free Cash Flow	4.71M
FCF Per Share	0.01

Full Cash Flow Statement

Margins

Gross margin is 88.98%, with operating and profit margins of 4.20% and -4.40%.

Gross Margin	88.98%
Operating Margin	4.20%
Pretax Margin	-1.14%
Profit Margin	-4.40%
EBITDA Margin	5.29%
EBIT Margin	4.20%
FCF Margin	1.59%

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.22%
Shareholder Yield	n/a
Earnings Yield	-2.01%
FCF Yield	0.73%

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.19. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.19
Piotroski F-Score	n/a